Changes in Immune Reactivity in Cancer Patients

Česká verzia

Authors: J. Kopecký ¹; L. Slováček ²; P. Priester ²; MUDr. Birgita Slováčková, Ph.D. ³; O. Kopecký ^4,5
Authors place of work: Klinika onkologie a radioterapie, LF UK a FN Hradec Králové ¹; Klinika onkologie a radioterapie, FN Hradec Králové ²; Psychiatrická klinika, FN Hradec Králové ³; Oddělení klinické onkologie, Oblastní nemocnice Náchod a. s. ⁴; Oddělení klinické imunologie a mikrobiologie, Oblastní nemocnice Náchod a. s. ⁵
Published in the journal: Klin Onkol 2012; 25(2): 97-102
Category: Reviews

Summary

It appears that the long-accepted paradigm that cytostatic and radiation therapy cause only immunosuppression, is not so clearly true. With regard to new knowledge in cancer immunology field, it seems that not only cytostatic and radiation therapy plays an important role in the alteration of immune system. There are many other factors influencing immunity like tumour environment itself, the use of immunomodulatory drugs or even the mental condition of cancer patients. The aim of review is to familiarize physicians with possible alterations of the immune system in cancer patients.

Key words:
immune system – chemotherapy – depression – glucocorticoids – radiotherapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
28. 11. 2011

Accepted:
12. 1. 2012

Zdroje

1. Haus E, Smolensky MH. Biologic rhythms in the immune system. Chronobiol Int 1999; 16(5): 581–622

2. Suzuki S, Toyabe S, Moroda T et al. Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol 1997; 110(3): 500–508.

3. Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010; 1193(1): 48–59.

4. Bertouch JV, Roberts-Thomson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Br Med J 1983; 286(6372): 1171–1172.

5. Lévi FA, Canon C, Touitou Y et al. Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. J Clin Invest 1988; 81(2): 407–413.

6. Mackall CL, Fleisher TA, Brown MR et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89(10): 3700–3707.

7. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995; 85(10): 2654–2670.

8. Eismann EA, Lush E, Sephton SE. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. Psychoneuroendocrinology 2010; 35(7): 963–976.

9. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24(34): 5373–5380.

10. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001; 167(11): 6497–6502.

11. Rutkowski MJ, Sughrue ME, Kane AJ et al. Cancer and the complement cascade. Mol Cancer Res 2010; 8(11): 1453–1465.

12. Markiewski MM, DeAngelis RA, Benencia F et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9(11): 1225–1235.

13. Su YB, Sohn S, Krown SE et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22(4): 610–616.

14. Anaissie EJ, Kontoyiannis DP, O’Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129(7): 559–566.

15. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8(2): 142–154.

16. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312(13): 818–822.

17. Kang DH, Weaver MT, Park NJ et al. Significant impairment in immune recovery after cancer treatment. Nurs Res 2009; 58(2): 105–114.

18. Casares N, Pequiqnot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin induced tumor cell death. J Exp Med 2005; 202(12): 1691–1701.

19. Apetoh L, Ghiringhelli F, Tesniere A et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220(1): 47–59.

20. Correale P, Cusi MG, Del Vecchio MT et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen- specific CTL response with antitumor activity in vitro. J Immunol 2005; 175(2): 820–828.

21. Carson WE 3^rd, Shapiro CL, Crespin TR et al. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004; 10(10): 3401–3409.

22. Lacour S, Hammann A, Wotawa A et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61(4): 1645–1651.

23. Micheau O, Solary E, Hammann A et al. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89(11): 783–789.

24. Galetto A, Buttiglieri S, Forno S et al. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003; 14(10): 833–843.

25. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4⁺ CD25⁺ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56(5): 641–648.

26. Lutsiak ME, Semnani RT, De Pascalis R et al. Inhibition of CD4(⁺) 25⁺ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105(7): 2862–2868.

27. Vicari AP, Luu R, Zhang N et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58(4): 615–628.

28. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202(12): 1691–1701.

29. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature dendritic cells into TGF-b secreting cells inducing CD4⁺ CD25⁺ regulatory T cells proliferation. J Exp Med 2005; 202(7): 919–929.

30. Suzuki E, Kapoor V, Jassar AS et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11(18): 6713–6721.

31. Plate JM, Plate AE, Shott S et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54(9): 915–925.

32. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62(8): 2353–2358.

33. Shindo H, Ogura T, Masuno T et al. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 1985; 20(2): 145–150.

34. Ujhazy P, Zaleskis G, Mihich E et al. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 2003; 52(7): 463–472.

35. Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14(8): 2413–2420.

36. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94(2): 259–267.

37. Gasser S, Orsulic S, Brown EJ et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436(7054): 1186–1190.

38. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203(5): 1259–1271.

39. Hareyama M, Imai K, Ban T et al. Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells - immunological study using monoclonal antibodies. Nihon Igaku Hoshasen Gakkai Zasshi 1988; 48(12): 1572–1574.

40. Gaugler MH, Squiban C, van der Meeren A et al. Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int J Radiat Biol 1997; 72(2): 201–209.

41. Lugade AA, Moran JP, Gerber SA et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174(12): 7516–7523.

42. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9(1): 6–19.

43. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 2004; 3(8): 715–718.

44. Riccardi C, Bruscoli S, Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002; 45(5): 361–368.

45. Liden J, Rafter I, Truss M et al. Glucocorticoid effects on NF-kB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun 2000; 273(3): 1008–1014.

46. Cronstein BN, Kimmel SC, Levin RI et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992; 89(21): 9991–9995.

47. Wertheim WA, Kunkel SL, Standiford TJ et al. Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. J Immunol 1993; 151(4): 2166−2175.

48. Pype JL, Dupont LJ, Menten P et al. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am J Respir Cell Mol Biol 1999; 21(4): 528−536.

49. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004; 1024: 124–137.

50. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024: 138–146.

51. Rozkova D, Horvath R, Bartunkova J et al. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol 2006; 120(3): 260–271.

52. Roland CL, Lynn KD, Toombs JE et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009; 4(11): e7669.

53. Roland CL, Dineen SP, Lynn KD et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009; 8(7): 1761–1771.

54. Huang Y, Chen X, Dikov MM et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(2): 624–631.

55. Lee SC, Srivastava RM, López-Albaitero A et al. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011; 50(2–3): 248–254.

56. Thornton LM, Andersen BL, Crespin TR et al. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun 2007; 21(2): 185–194.

57. Koga C, Itoh K, Aoki M et al. Anxiety and pain suppresses the natural killer cell activity in oral surgery outpatients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91(6): 654–658.

58. Bachen EA, Manuck SB, Marsland AL et al. Lymphocyte subset and cellular immune responses to a brief experimental stressor. Psychosom Med 1992; 54(6): 673–679.

59. Zakowski SG, McAllister CG, Deal M et al. Stress, reactivity and immune function in healthy men. Health Psychol 1992; 11(4): 223–232.

60. Gabbay V, Klein RG, Alonso CM et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 2009; 115(1–2): 177–182.

61. Zorrilla EP, Luborsky L, McKay JR et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15(3): 199–226.

62. Szuster-Ciesielska A, Słotwińska M, Stachura A et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 686–694.

63. Wong ML, Dong C, Maestre-Mesa J et al. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13(8): 800–812.

64. Holden RJ, Pakula IS, Mooney PA. An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med Hypotheses 1998; 51(4): 309–314.

65. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007; 21(4): 374–383.

66. Simon NM, McNamara K, Chow CW et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008; 18(3): 230–233.